Literature DB >> 15741482

Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users.

Jonathan P Roiser1, Lynnette J Cook, Jason D Cooper, David C Rubinsztein, Barbara J Sahakian.   

Abstract

OBJECTIVE: The long-term effects of the use of 3,4-methylenedioxymethamphetamine (MDMA, or Ecstasy) in humans are controversial and unclear. The authors' goal was to assess the contribution of a functional polymorphism in the gene encoding serotonin transporter to changes in emotional processing following chronic Ecstasy use.
METHOD: They investigated Beck Depression Inventory scores and performance on the Affective Go/No-Go test, a computerized neuropsychological test sensitive to emotional processing, in Ecstasy users and comparison subjects, stratifying the results by serotonin transporter genotype.
RESULTS: Ecstasy use was associated with higher Beck Depression Inventory score and abnormalities in the Affective Go/No-Go test in individuals with the ss and ls genotype but not those with the ll genotype.
CONCLUSIONS: Ecstasy users carrying the s allele, but not comparison subjects carrying the s allele, showed abnormal emotional processing. On the basis of a comparison with acute tryptophan depletion, the authors hypothesize that chronic Ecstasy use may cause long-term changes to the serotonin system, and that Ecstasy users carrying the s allele may be at particular risk for emotional dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15741482      PMCID: PMC2631647          DOI: 10.1176/appi.ajp.162.3.609

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  18 in total

1.  The BDI of the beholder.

Authors:  J C Cole; H R Sumnall
Journal:  J Psychopharmacol       Date:  2002-03       Impact factor: 4.153

2.  Acute dietary tryptophan depletion impairs maintenance of "affective set" and delayed visual recognition in healthy volunteers.

Authors:  J S Rubinsztein; R D Rogers; W J Riedel; M A Mehta; T W Robbins; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

3.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

4.  Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine.

Authors:  L Matuszewich; M E Filon; D A Finn; B K Yamamoto
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

5.  Tryptophan depletion during continuous CSF sampling in healthy human subjects.

Authors:  L L Carpenter; G M Anderson; G H Pelton; J A Gudin; P D Kirwin; L H Price; G R Heninger; C J McDougle
Journal:  Neuropsychopharmacology       Date:  1998-07       Impact factor: 7.853

6.  Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms.

Authors:  N MacInnes; S L Handley; G F Harding
Journal:  J Psychopharmacol       Date:  2001-09       Impact factor: 4.153

Review 7.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

8.  Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression.

Authors:  Alexander Neumeister; Anastasios Konstantinidis; Juergen Stastny; Markus J Schwarz; Oliver Vitouch; Matthaus Willeit; Nicole Praschak-Rieder; Johanna Zach; Martina de Zwaan; Brigitta Bondy; Manfred Ackenheil; Siegfried Kasper
Journal:  Arch Gen Psychiatry       Date:  2002-07

9.  The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers.

Authors:  F C Murphy; K A Smith; P J Cowen; T W Robbins; B J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2002-07-13       Impact factor: 4.530

10.  The effects of tyrosine depletion in normal healthy volunteers: implications for unipolar depression.

Authors:  Andrew McLean; Judy S Rubinsztein; Trevor W Robbins; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-09-04       Impact factor: 4.530

View more
  20 in total

1.  The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.

Authors:  Jonathan P Roiser; Robert D Rogers; Lynnette J Cook; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2006-08-29       Impact factor: 4.530

2.  Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion.

Authors:  Abigail A Marsh; Elizabeth C Finger; Beata Buzas; Niveen Soliman; Rebecca A Richell; Meena Vythilingham; Daniel S Pine; David Goldman; R J R Blair
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

3.  Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.

Authors:  Samanta Yubero-Lahoz; K P C Kuypers; J G Ramaekers; Klaus Langohr; Magí Farré; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2014-12-20       Impact factor: 4.530

4.  Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.

Authors:  Amanda M George; Tim D Windsor; Bryan Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2010-12-08       Impact factor: 4.530

5.  Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use.

Authors:  Krista Lisdahl Medina; Paula K Shear
Journal:  Drug Alcohol Depend       Date:  2006-10-30       Impact factor: 4.492

6.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

Review 7.  The genetics of bipolar disorder.

Authors:  J H Barnett; J W Smoller
Journal:  Neuroscience       Date:  2009-04-07       Impact factor: 3.590

8.  Differential effects of 5-HTTLPR genotypes on mood, memory, and attention bias following acute tryptophan depletion and stress exposure.

Authors:  Christine Firk; C Rob Markus
Journal:  Psychopharmacology (Berl)       Date:  2008-12-16       Impact factor: 4.530

Review 9.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

10.  Association of the serotonin transporter gene promoter region (5-HTTLPR) polymorphism with biased attention for emotional stimuli.

Authors:  Christopher G Beevers; Tony T Wells; Alissa J Ellis; John E McGeary
Journal:  J Abnorm Psychol       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.